FDA lifts clinical hold from Mersana’s breast cancer trial

FDA lifts clinical hold from Mersana’s breast cancer trial

Source: 
Fierce Biotech
snippet: 

The FDA has lifted the partial clinical hold it placed on a phase 1 trial of Mersana Therapeutics’ HER2-targeted antibody-drug conjugate (ADC). Regulatory officials put enrollment in the XMT-1522 breast cancer trial on hold in July after learning of the death of a participant.